The complexity of tumor vascularity

Cancer Biology and Therapy

Volumn 2, Issue 3, 2003, Pages 257-258

  Sood, Anil K ^a   Hendrix, Mary J C ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Breast cancer; Vasculogenesis

Indexed keywords

ANGIOPOIETIN RECEPTOR; CD133 ANTIGEN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; TUMOR MARKER; VASCULOTROPIN RECEPTOR 2;

BLOOD; BREAST TUMOR; DISEASE COURSE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NOTE; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANTIGENS, CD; BREAST NEOPLASMS; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; RECEPTOR, TIE-2; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 85047688277     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.2.3.380     Document Type: Note

References (27)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-57.
2. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci 2000; 97:14608-13. (Pubitemid 32016623)
3. Dome B, Paku S, Somlai B, Timár J. Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance. J Pathol 2002; 197:355-62. (Pubitemid 34778306)
4. Holash J, Marisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoientins and VEGF. Science 1999; 284:1994-8. (Pubitemid 29309448)
5. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999; 18:5356-62. (Pubitemid 29462372)
6. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-6.
7. Folkman J. Clinical applications of research on angiogenesis. Seminars in medicine of the Beth Israel Hospital, Boston. N Engl J Med 1995; 333:1757-63.
8. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nature Med 2000; 6:389-95. (Pubitemid 30208155)
9. Kumar R, Fidler IJ. Angiogenic molecules and cancer metastasis. In vivo 1998; 12:27-34. (Pubitemid 28177276)
10. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv Cancer Res 1996; 69:135-74. (Pubitemid 26274885)
11. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000; 21:505-15. (Pubitemid 30137936)
12. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407:242-248.
13. Pezella F, Pastorino U, Tangliabue E, Androla S, Sozzi G, Gasparini G, et al. Am J Pathol 1997; 151:1417-23.
14. Breast Cancer Progression Working Party. Evidence for novel non-angiogenic pathway in breast-cancer metastasis. The Lancet 2000; 355:1787-8.
15. Sussman LK, Upalakalin JN, Roberts MJ, Kocher O, Benjamin LE. Blood markers for vasculogenesis increase with tumor progression in patients with breast carcinoma. Cancer Biol Therapy 2003; 2:http://www.landesbioscience.com/ journals/cbt/abstract.php?id=363.
16. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60:1388-93. (Pubitemid 30152012)
17. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86:353-64. (Pubitemid 26272076)
18. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LMG, Pe'er J, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry. Am J Pathol 1999; 155:739-52. (Pubitemid 29426820)
19. Folberg R, Hendrix MJC, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000; 156(2):361-81. (Pubitemid 30648785)
20. Sharma N, Seftor REB, Seftor EA, Gruman, Heidger PM, Cohen MB, et al. Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. The Prostate 2002; 50:189-201. (Pubitemid 34137446)
21. Liu C, Huang H, Doñate F, Dickinson C, Santucci R, El-Sheikh A, et al. Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res 2002, 62:5470-5.
22. Shirakawa K, Kobayashi H, Heike Y, Kawamoto S, Brechbiel MW, Kasumi F, et al. Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res 2002; 62:560-6. (Pubitemid 34106432)
23. Shirakawa K, Tsuda H, Heike Y, Kato K, Asada R, Inomata M, et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 2001; 61:445-51. (Pubitemid 32128594)
24. Shirakawa K, Wakasugi H, Heike Y, Watanabe I, Yamada S, Saito K, et al. Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer 2002; 99:821-8. (Pubitemid 34575699)
25. Hendrix MJC, Seftor EA, Kirschmann DA, Seftor REB. Molecular biology of breast cancer metastasis: molecular expression of vascular markers by aggressive breast cancer cells. Breast Cancer Res 2000; 2:417-22. (Pubitemid 32223638)
26. Sood AK, Fletcher MS, Hendrix MJC. The embryonic-like properties of aggressive human tumor cells. J Soc Gynecol Investig 2002; 9:1-9.
27. Sood AK, Seftor EA, Fletcher MS, Gardner LMG, Heidger PM, Buller RE, et al. Molecular determinants of ovarian cancer plasticity. Am J Pathol 2001; 158:1279-88. (Pubitemid 32281292)